Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Nabla Bio

Explore full profile

Developing AI and wet-lab technologies to enable the rational design of selective, functional drugs targeting previously undruggable sites

Cambridge, United StatesFounded 2020Biotech & Life Sciences
Valuation $100–250M Last recorded · 2024
Revenue <$1M Latest reported FY
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Nabla Bio and the history behind them.

About Nabla Bio

Nabla.bio is a cutting-edge biotechnology startup specializing in protein engineering through advanced deep learning techniques. The company operates in the biotech and pharmaceutical markets, focusing on developing innovative solutions for protein design and engineering. Their primary clients include pharmaceutical companies, biotech firms, and academic research institutions that require precise and efficient protein engineering for drug development, therapeutic treatments, and scientific research.

Read full description

Nabla.bio's core offering is its proprietary AbMap™ Platform, which leverages deep representation learning—a type of artificial intelligence that helps computers understand complex data—to engineer proteins more effectively and efficiently. This platform allows for "unified rational protein engineering," meaning it uses a systematic and logical approach to modify proteins based on their sequences. The company also excels in "low N protein engineering," which refers to creating effective protein designs even with limited data, thanks to their data-efficient deep learning models.

The business model of Nabla.bio revolves around providing access to its AbMap™ Platform through licensing agreements, partnerships, and collaborative projects. By offering their technology to other companies and research institutions, Nabla.bio generates revenue through licensing fees, research grants, and service contracts. This model not only ensures a steady income stream but also fosters innovation and collaboration within the biotech community.

In summary, Nabla.bio is revolutionizing the field of protein engineering with its state-of-the-art deep learning technology, serving a niche market of biotech and pharmaceutical clients who demand high precision and efficiency in protein design.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2020
Headquarters
Cambridge, United States
Employees
23
Open positions
6
Dealroom signal
85.1/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Drug Development, Synthetic Biology, Spinout, Biotech and Pharma, Techbio, YC S20, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
b2b

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC May 2024 $26M $104M Bristol-Myers Squibb · Radical Ventures · Takeda Ventures · AstraZeneca ↗
SEED✓Equity / VC Dec 2021 $11M $44M Fifty Years · Khosla Ventures · Zetta Venture Partners · Cantos Ventures ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Nabla Bio website traffic

Latest recorded traffic for Nabla Bio is 8.8K monthly website visits, up 57.1% over the last three months. Nabla Bio's team grew 4.5% over the past year.

Latest monthly visits8.8K 3-month web change+57.1% 1-year team growth+4.5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

CompanyHeadquartersStatusEmployeesTotal fundingValuation
Proxima BioFormerly VantAI. Proximity therapeutics hijacking cellular machinery for protein degradation New York City, United States Operational 77 $80M $320M
1910 GeneticsA biotechnology company integrating AI, computation, and biological automation to accelerate the design of small molecule and protein therapeutics Boston, United States Operational
Sibylla BiotechFacing the complexity of drug discovery with the power of an innovative approach for meeting unmet medical needs Bresso, Italy Operational
Menten AILeverages synthetic biology, machine learning and quantum computing to create new proteins not found in nature for diverse applications in the pharmaceutical and chemical industries San Francisco, United States Operational
Octarine BioHarnessing the powers of synthetic biology to develop rare and superior cannabinoids and psychedelic derivatives Copenhagen, Denmark Operational
AbSciThe global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry Vancouver, United States Operational
InterAx BiotechDelivering High-Quality Drug Candidates for GPCR Targets Villigen, Switzerland Operational
AI ProteinsA newly founded biotechnology company focused on the design and engineering of synthetic miniprotein therapeutics Andover, United States Operational
Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

Series A4 investors entered at this stage

  • Bristol-Myers Squibb
  • Radical Ventures
  • Takeda Ventures
  • AstraZeneca

Other known investors2 additional known investors

  • Harvard University
  • BluePointe Ventures
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Nabla Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Nabla Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.